ࡱ> Root Entry9l a!&FileHeaderaDocInfoVHwpSummaryInformation.N "#$%&'()*+-/.,0123Root Entry9l a&FileHeaderaDocInfoVHwpSummaryInformation.N 8] <\><Recent Advances in Immuno-Oncology> <\Դ><During immune responses, antigen-specific T cells are regulated by various mechanisms including inhibitory receptors and regulatory T cells to avoid excessive and persistent immune responses. These regulatory mechanisms, called  immune checkpoint , suppress T cell responses particularly in chronic viral infection and cancer, in which viral antigens or tumor antigens persist for a longtime, and contribute to T cell exhaustion in patients with chronic viral infection or cancer. Among them, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) are the most well-known receptors and have been targeted for drug development. As a result, anti-CTLA-4 and anti-PD-1 (or anti-PD-L1) blocking antibodies were developed for cancer treatment and known as  immune checkpoint inhibitors . In this seminar lecture, recent advances in immuno-oncology, including immune checkpoint inhibitors, will be discussed.> <\Ԑ>< X > <Y% (Yլt)><>lGIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`iTݵtʥ-[uẃ+^̸1Ð#KL˘쐳X,ƥ [`Q+Z`՝9KP[oiӥ궈4y>s{nz OO>7LM'7}#Ot?']]}z^H6C4r]Ѓ Eau n6Ztj'v`szU t3\g*Ft}6`Qdia撑&2y8Inf eQw| A\_7nHfC]wsfHm8=gr=鑔^Y[mh0"W>qa Gtȩy~Jrv=)銃2~&ꠤ(ln4e2ˢj+%+ryʷꦜYa袆 +FŢnB$MIgN-`^ʩ*믷жo z KZRBᬽIHka쩏l>b`>6igڻ "7LHk4N[gWy\6{n0-) gZܭ$'|-ޛT6y?k<ԃ_&׌{M߉ *ZI3lG_s} ?j[uCK%ru}90۴Eߚ^:1;챻idFb뛶_z=ҜT]>%Q_Z9F3  jDvĪd';#^Ѐ:jv'5:bJ'/Pk_|H4h^ݩ&Rޛry),L:֦LVLzklj6n3e(Oj W{S󍖵;=o J6p,6ڡv]$n,sNAll2mjj<"PTnwsEm\+jڣp׻v5/xO7U]G+_Ľo 3]NB/6X=Wb)^鎗J07)_ 7+lQ|Mpyb7(5ix81{b!DZqT52L['dz.d1,Z5#gyҪ͠<؞90FFѸ h:ؐ<w.1KQt[M7&%2^  spunb{h~Z]sCfp> eS{45,mS7;6d:ܞ<_"{t|ny7;1gomzlsFv}of'5>m:Cω%p_x]7C;㈌Wb;0gN8Ϲw@ЇNHOҗ;PI@;a`0x`a``a`0x  t  ajou2010D 2 10| ”| $ 2:36:28Shin-9, 1, 0, 2170 WIN32LEWindows_Unknown_Version@m @l a@4Ԉxş b=C9zVkAv&65X{B)Zz,z"Qъ-4Ԉx?A<B9 ؋уAn$ki0?}eQ,Y8%*Ǻ{I)rn1jZƖH)ba(2,5n"eKA\AaI&P25ZM!=] L(s]em0n!+\1Yh`f3PkE;XVdl!IA3 B M 9ԅ#K+Cߥ?Pr%9D+`-c i;d/]_9Q>a KXW 1`ǩJE9}2˯뮪VvS${7ԞAWz)?2Z0?UOs}SMwSL{~bG0U~[woi;6YÖSA fw'pg͇#Llұαuڇl;Q-Ȋ^\]Lݽ1+2tT,TDLfb2A>&ɳg2ӵ8̨*:ز"<5͗7|wDs-ҧ ir@RZ4)#0ʷx`7ac}r$풿kA?;7cs hHWP Document File-T0LP$r.+mD 3(6əy4?zSvgvxϼ}ʹ=rG,r{3KCq4'+mv2Fgh ; \Ka kt>3`'R &v Fga="e* )5GU5pVGe(;9.Za&bz. O)A%Y?,vő?>t\}vUG1z\eNvFʊ:6S2jVfuE0-ު Zkaғ*c݊._6~Oi?_*bO=9.VeMٳ Sr|r5Z!TDeڽ#mhM~Nߥu@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#< coyL0As,1`ec9D"1cd߈-PD-L1) blocking antibodies were developed for cancer treatment and known as  immune checkpoint inhibitors . In this seminar lecture, recent advances in immuno-oncology, including immune checkpoint inhibitors, will be discussed.> <\Ԑ>< X > <Y% (Yլt)><>WMhU>3oLۨYhHۀ$PmpӄXi )(׼ަh.\E _],,..nZ{/5:}3s~;޹oF?YhQPW9NXӤbk8z!zyV[>AV[hSָRM қSu F1 6bzw2h9v1|8cwB_Cpqsai ~ b2WiGb m5A͜ YՕ~%Z5ò >쾶٦jqrږۚ6/-%ݒ8?ɯw9}<'=T, ?(\ZLB8=Iy[Ϥd1/ֈsB~+&\#QSrU [q/O%y "W%#1XKWׄ/qwlTVĪ%?@ABCDEFGHIJKLMOPQRSTUWXYZ[\]^_`ebcdfghijklnorstuvwxy{|}~BodyText l al aPrvImage ^ PrvTextDocOptions 9l a9l aSection0znwCYz1TEbB":t ~].8~g1cw6+}٘_;L6ElVec9٘O) Lp6f/A/eciyW1gc4ۙl"lgc{P3u݃e7S);mth;fC.WqPlYc 鿼)f탫;Ӈ=l otk7;C>BTMKQ=ofLU,4Ԋh ]5" fvJkqbՀwnKGҴKt3 ]B6 o&L>^L9h@VUA,+  Fs{ c{"ӰMuZP)@\?rgڐIQjddBId>e>{#S^Q2PE:*3X21hN"/A:u3#p+'J8S$Iu]nMyV)D%d $Kc L`qQh紒M K6yg<@뿂ʧC,x9Mn8$Iy'q{cc5?8} ]vOL HުM+ 0WJO_W+S2AD@o+)QWheax{/_O^[xE,ţ8%-4^-`)56hO`%?@ABCDEFGHIJKLMOPQRSTUWXYZ[\]^_`ebcdfghijklnorstuvwxy{|}~